Cholangiocarcinoma Linked to BRAF V600 Responds to Dual Drug Combo
According to a publication from CURE Magazine, in a phase 2 clinical trial nearly 50% of patients with a certain type of cholangiocarcinoma responded to a treatment comprised of two…